Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease
Open Access
- 16 August 1990
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (7) , 445-448
- https://doi.org/10.1056/nejm199008163230704
Abstract
There is no effective pharmacologic treatment for Alzheimer's disease, the most common dementing illness in the United States. Hydergine, a combination of ergoloid mesylates, is the only approved medication for Alzheimer's disease, but despite widespread use its efficacy remains to be established. We conducted a clinical trial of Hydergine-LC, a newer preparation of ergoloid mesylates in the form of a liquid in a capsule (LC) that may have greater bioavailability, to determine its value in patients with Alzheimer's disease.Keywords
This publication has 10 references indexed in Scilit:
- The Alzheimer's disease imperative: the challenge for psychiatryAmerican Journal of Psychiatry, 1988
- Alzheimer's DiseaseNew England Journal of Medicine, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Development and Validation of the Geriatric Evaluation by Relative's Rating Instrument (Gerri)Psychological Reports, 1983
- An overview of pharmacologic treatment of cognitive decline in the agedAmerican Journal of Psychiatry, 1981
- Pathological verification of ischemic score in differentiation of dementiasAnnals of Neurology, 1980
- An Ergot Alkaloid Preparation (Hydergine) in the Treatment of Dementia: Critical Review of the Clinical LiteratureJournal of the American Geriatrics Society, 1976
- A multiple scoring method for the assessment of complex memory functions.Journal of Consulting and Clinical Psychology, 1975
- “Mini-mental state”Journal of Psychiatric Research, 1975
- Development of a Rating Scale for Primary Depressive IllnessBritish Journal of Social and Clinical Psychology, 1967